Syner-G Pharma CMC Consulting | CMC Regulatory Affairs
16302
page,page-id-16302,page-template,page-template-full_width,page-template-full_width-php,ajax_updown_fade,page_not_loaded,boxed,,qode-theme-ver-6.0,wpb-js-composer js-comp-ver-4.12,vc_responsive

CMC Regulatory Affairs

header-cmc

Expert CMC Regulatory Solutions
...Science-Based, Customized and Strategic or Tactical

The continuously evolving CMC regulatory landscape presents a steady challenge to the development of new drugs and biologics.  For example, regulator’s expectation to adopt new paradigms of drug development (e.g. QbD/PAT) and increased testing and controls can add major CMC challenges in the current climate of globalized and outsourced R&D and manufacturing settings.  The opportunity for expedited regulatory pathways pose additional CMC challenges for the timely development of a commercial ready process.  These scenarios are further confounded by the lack of harmonized global regulations. At Syner-G, we have extensive experience in navigating this landscape and are passionate in helping our clients in the design, planning and execution of CMC strategies critical for the successful development and timely approval of new drugs.

Whether you seek expert regulatory advice for regulatory starting materials selection, identifying control strategies for genotoxic impurities, or help in strategizing and preparing briefing documents or CTD Modules 3 and 2 of regulatory submissions, we have qualified professionals to support your specific regulatory requirements. Our staff comes from the pharma industry and the FDA, with proven expertise in all areas of CMC Regulatory Affairs to support global clinical trials and market authorization applications. We are adept in designing phase appropriate and product specific CMC strategies that are the key to successful and expedited drug development.

Syner-G’s Services

Typically, regulatory activities follow the 80:20 rule, i.e. 80% are tactical and 20% are strategic. Syner-G offers both strategic and tactical CMC solutions. Strategic CMC regulatory solutions are designed on a case-by-case basis by evaluating the scientific and technical situation and challenges whereas tactical solutions are primarily geared towards the execution of the strategy.

CMC Regulatory Affairs

Strategic CMC Services

  • Define the “Right Content” for all regulatory submissions
    • Investigational applications (IND/IMPD/CTA/CTX)
    • Marketing application (NDA/MAA/NDS)
    • Type II Drug Master Files (DMF)
  • Manage critical quality issues during development
    • Genotoxic impurities/ Degradants, Stability
    • Material/Process Controls, Specification
    • Formulation/process changes during development
  • Change management
    • Investigational stages
    • Post-approval stages
  • Regulatory Agency meetings (Pre-IND, EOP-2, Pre-NDA, Type C, Scientific Advice)
  • QbD: Commercial product/ process/ control-strategy
  • Responses to Regulatory Agency inquiries
  • CMC Regulatory due-diligence (for in-license or out-license)

Tactical CMC Services

  • eCTD Documentation (Module 3/ Module 2.3 QOS)
    • Investigational applications (IND/IMPD/CTA) and Amendments
    • Marketing applications (NDA/MAA/NDS)
    • sNDA (post approval PAS or CBE) / Variations
    • Type II Drug Master Files (DMF)
  • Annual Report Documentation
    • INDs
    • NDAs
    • DMFs
  • CMC submission Project Management
  • Regulatory submissions
  • Liaison services with regulatory Agencies
  • CMC Regulatory conformance Gap Analysis and Remediation
  • CMC Annual Product Review
  • CMC Report writing (Development, Stability, Validation)

HOW CAN WE HELP YOU?

Contact Us